Fig. 3From: Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysisTrend in monthly overall expenditure (A) and DDDs (B) of 12 anticancer drugs from 2017 to 2019Back to article page